Sign In
Buy ALLK
$0.329
+0 (+0%)
At Close: Aug 14, 2025
45% (181/405) of patients with chronic functional gastrointestinal symptoms who underwent upper endoscopy with biopsy met the diagnostic criteria for eosinophilic gastritis and/or eosinophilic duo
Bear Of The Day: Allakos (ALLK)
11:16am, Friday, 21'st May 2021
Bear Of The Day: Allakos (ALLK)
7 of the Best Pharma Stocks to Buy Now
10:37am, Tuesday, 11'th May 2021
As the market gets back to normal, it's a great time to explore the pharma stocks that got lost in the vaccine frenzy of the past year. The post 7 of the Best Pharma Stocks to Buy Now appeared first o
Allakos Reports First Quarter 2021 Financial Results and Provides Business Update
04:01pm, Monday, 10'th May 2021
REDWOOD CITY, Calif., May 10, 2021 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast
Allakos: Prevalence Data Shows A Large Undiagnosed Market
07:42am, Sunday, 21'st Mar 2021
Allakos has a molecule targeting a largely undiagnosed market. If their prevalence study is any good, the potential for the therapy is huge.
Abercrombie, Mattel, Western Digital and More Wednesday Afternoon Analyst Calls
12:27pm, Wednesday, 24'th Feb 2021
With the trading day more than halfway over, the broad markets have pushed higher, seemingly recovering from Tuesday.
Are Options Traders Betting on a Big Move in Allakos (ALLK) Stock?
12:02pm, Wednesday, 06'th Jan 2021
Investors need to pay close attention to Allakos (ALLK) stock based on the movements in the options market lately.
Allakos Appoints Natalie Holles to its Board of Directors
04:05pm, Tuesday, 22'nd Dec 2020
REDWOOD CITY, Calif., Dec. 22, 2020 (GLOBE NEWSWIRE) -- Allakos Inc. (NASDAQ: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-related disea
Allakos Reports Third Quarter 2020 Financial Results and Provides Business Update
08:01am, Monday, 09'th Nov 2020
REDWOOD CITY, Calif., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mas
Allakos Announces Pricing of Public Offering of Common Stock
08:20pm, Wednesday, 28'th Oct 2020
REDWOOD CITY, Calif., Oct. 28, 2020 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell related
Allakos Previews Preliminary Financial Results for the Three Months Ended September 30, 2020
07:56pm, Tuesday, 27'th Oct 2020
REDWOOD CITY, Calif., Oct. 27, 2020 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK) (“Allakos” or “the Company”), a biotechnology company developing AK002 for the treatment of eosinophil and m
Allakos Announces Proposed Public Offering of Common Stock
04:09pm, Tuesday, 27'th Oct 2020
REDWOOD CITY, Calif., Oct. 27, 2020 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell related
Zacks Investment Research Upgrades Allakos (NASDAQ:ALLK) to “Hold”
04:46am, Wednesday, 14'th Oct 2020
Zacks Investment Research upgraded shares of Allakos (NASDAQ:ALLK) from a strong sell rating to a hold rating in a research report report published on Tuesday morning, Zacks.com reports. According to
Oct 08, 2020 (The Expresswire) --
Global "Adhesion Barrier Market" (2020-2025) Industry Research Report is an expert and inside and out examination on the...
Allakos Reports Second Quarter 2020 Financial Results and Provides Business Update
12:00pm, Monday, 10'th Aug 2020
REDWOOD CITY, Calif., Aug. 10, 2020 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell-related
